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Abstract
Background: Intensive rehabilitation of patients with severe traumatic brain injury is generally applied in the
subacute stages of the hospital stay. Few studies have assessed the association between early and intensive
physical rehabilitation and functional outcomes. The aim of this trial is to assess the feasibility of an intensive
physical rehabilitation intervention focusing on mobilisation to the upright position, starting as early as clinically
possible versus standard care in the intensive care unit. The feasibility study is intended to inform a subsequent
randomised clinical trial that will investigate benefits and harms of the intervention.
Methods: This randomised clinical feasibility trial with a follow-up period of 1 year will use blinded outcome
assessors for the Coma Recovery Scale–Revised. A maximum of 60 patients admitted to the neurointensive care
unit at Rigshospitalet, Denmark, with traumatic brain injury (age of at least 18 years), a low level of consciousness,
and stable intracranial pressure will be included in the trial. Patients will be randomly assigned to experimental
intervention versus standard care (1:1) stratified according to their Glasgow Coma Score. The intervention group will
receive daily mobilisation in a tilt table with an integrated stepping device (ERIGO®). Feasibility is declared if more
than 60% (the lower 95% confidence interval of the proportion) of eligible patients are included in the trial and
more than 52% (the lower 95% confidence interval of the proportion) of patients in the intervention group receive
more than 60% of the planned interventions. Safety is assessed by the occurrence of adverse events and adverse
reactions. Exploratory clinical outcomes consist of cerebral haemodynamics (blood flow velocity and pressure
autoregulation) and baroreceptor sensitivity in the early phase as well as functional outcomes (Coma Recovery
Scale–Revised, Early Functional Ability scale, and Functional Independence Measure).
Discussion: Our findings will inform a future, larger-scale randomised clinical trial on early mobilisation using a tilt
table early after severe traumatic brain injury.
Trial registration: ClinicalTrials.gov identifier: NCT02924649. Registered on 3 October 2016.
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Background
Patients with severe acquired brain injury (ABI) may
benefit from early and intensive rehabilitation, which
partly consists of physical exercise [1]. Thus, observa-
tional studies have found an association between
higher-level physical activities and better final outcome
in these patients [1, 2]. However, such exercise poses an
orthostatic challenge and requires that the patient be
able to compensate for this challenge. Accordingly, for
patients with severe ABI and a low level of conscious-
ness, mobilisation to the upright position on a tilt table
is an important first step. Several beneficial effects are
hypothesised to result from this type of activity. In a re-
cent observational study, we showed that patients with
impaired consciousness open their eyes for longer pe-
riods of time in the upright compared with the lying
position, indicating increased arousal [3]; other authors
have confirmed this finding [4, 5] and reported that
head-up tilt (HUT) also reduced the risk of ankle contrac-
tures (range of motion) and improved lung function [6, 7].
On the other hand, mobilisation to the upright posi-
tion may trigger haemodynamic problems, including
hypotension and syncope, and may also pose a risk of
extubation in intubated patients, dislodgement of in-
dwelling catheters, and falls. About 40% of patients
with severe ABI have orthostatic intolerance that limits
their chance of achieving an upright position [3]. Nei-
ther the physiological mechanisms causing orthostatic
hypotension nor those that enable recovery from this
phenomenon have been thoroughly investigated. Con-
sidering analysis of electrocardiography (ECG) signals
obtained from ABI patients during HUT, we suggested
that impairment of baroreceptor sensitivity may be in-
volved [8]. Whether the impairment is caused by the
brain lesion per se or prolonged immobilisation or both
remains to be investigated. However, in other patient
populations with neurally mediated syncope or ortho-
static hypotension, intensive tilt-table training has been
shown to be beneficial for regaining neurovascular con-
trol [9, 10]. In addition, recent studies including a large
number of patients with ABI have found an association
between impaired cerebral autoregulation measured the
first days after injury and an unfavourable outcome
[11, 12]. In line with these results, we have shown
impaired autoregulation during HUT in patients with
severe ABI as late as 40 days after injury [8]. Thus, it
is possible that autoregulation and baroreceptor sensi-
tivity are progressively impaired with prolonged im-
mobilisation and that this further restricts attempts at
mobilisation in some of these patients, ultimately leading
to an impaired functional outcome.
Even though Andelic et al. found a beneficial effect of
early rehabilitation in patients with traumatic brain in-
jury (TBI) in their quasi-randomised trial [13], the net
effect of early mobilisation in patients with TBI remains
unclear. Also, mobilisation of patients with severe ABI is
usually not initiated in the acute stage after injury, during
the intensive care stay, but rather at a later, subacute stage
(weeks), after stabilisation and transfer for rehabilitation
[14]. A recent small study conducted in four patients with
acute severe TBI and disorders of consciousness suggested
that early mobilisation is feasible and safe using a tilt table
with integrated stepping that increases the venous return
of blood to the heart [15] but these data warrant replica-
tion in larger studies.
In February 2017, we conducted a thorough search of
the literature in relevant databases (MEDLINE, CINAHL,
EMBASE, CENTRAL, and Web of Science) on early
out-of-bed mobilisation in patients with TBI by using
Medical Subject Headings (MeSH) terms (brain injuries,
traumatic AND rehabilitation). The search showed that
no randomised trials have yet been performed in this field.
Therefore, we wish to assess the feasibility of an early
HUT protocol in patients with severe TBI, in terms not
only of the number of patients who are successfully
mobilised but also of the number of adverse events
(AEs) and adverse reactions (ARs). In exploratory ana-
lyses, we will assess clinical outcomes at 3 months and 1
year. Furthermore, we wish to explore physiological vari-
ables during ongoing mobilisation in the early phase and
their possible association with the patients’ clinical out-
come. Finally, as an exploratory part of this trial, we wish
to investigate the occurrence and time to recovery of
orthostatic tolerance and cerebral autoregulation in pa-
tients with severe TBI who receive early and intense mo-
bilisation and their relation to the functional outcome.
Methods/Design
This trial is a randomised clinical feasibility trial com-
paring an early HUT protocol versus standard care in a
neurointensive care unit (NICU) and a specialised neu-
rorehabilitation department. The protocol was developed
in accordance with the guidelines and checklists for
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) (Additional file 1) [16]. Results
will be reported as stated in the Consolidated Standards
of Reporting Trials (CONSORT) statement [17]. Random-
isation will be conducted centrally by the Copenhagen
Trial Unit using a web-based randomisation system. The
allocation sequence will be computer-generated using
block sizes of varying length concealed for the investiga-
tors. The allocation ratio is 1:1. Because consciousness
measured by the Glasgow Coma Scale (GCS) score can be
partly a predictor of outcome [18], the allocation sequence
will be stratified for GCS score at the time of inclusion
(3–6 points compared with 7–10 points). All included pa-
tients will be followed from inclusion until 1 year after in-
jury. All baseline assessments will be conducted before
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randomisation and start of intervention (time point − 1).
Cerebral blood flow autoregulation will be studied after 2
and 4 weeks. Functional assessments will be conducted
after 4 weeks, 3 months and 1 year (Fig. 1).
Blinding
It is not possible to blind the intervention for the treating
physical therapists or the participant. However, outcome
assessment using the Coma Recovery Scale–Revised
(CRS-R) will be conducted by assessors who are blinded
to the intervention. Data are entered in a validated Micro-
soft Excel spreadsheet by the primary investigator (CGR)
and will be checked for correctness against the source
data by a colleague otherwise not involved in the trial.
Furthermore, the person analysing the data will be blinded
to the patient’s randomisation, and concealed allocation
will be revealed only after all analyses have been com-
pleted and two conclusions drawn [19].
Recruitment and informed consent
Patients admitted to the NICU will be screened for eligi-
bility on a daily basis by the principal investigator
(CGR). The nearest relative to the patient acts as proxy
(next of kin) and is given written information about par-
ticipation in the trial. The relative is then invited to an
information meeting. The relatives are informed that they
can withdraw their consent at any time. If consent is
given, a medical doctor not involved in the trial but acting
as trial guardian is asked to give consent as well. Written
informed consent must be obtained from the patient him-
self or herself if he or she regains consciousness and
decision-making capability during the trial period.
Participants
Participants included in this trial must be admitted to the
NICU at Rigshospitalet, Copenhagen, Denmark, with
severe TBI, be at least 18 years old, and have a clinical
presentation that does not exclude a later diagnosis of
vegetative state or minimally conscious state or a GCS
score of lower than 11 points during wake-up call, and
stable intracranial pressure of less than 20 mm Hg for
24 h, and informed consent from the nearest relative and
trial guardian must be in place. Patients with unstable
fractures or other injuries that contraindicate mobilisation,
patients with spinal cord injury, or patients without rele-
vant informed consent are excluded from the trial.
Time schedule
We will include patients until January 1, 2019 or until a
maximum of 60 patients have been included, whichever
Fig. 1 SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) table of enrollment, intervention, and assessments
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occurs first. For a detailed flowchart on patient inclu-
sion, please refer to Fig. 2. Data analysis will commence
3 months after (April 1, 2019). At this time, the 1-year
follow-up will most likely not be complete for all pa-
tients. This variable will remain blinded until all data are
gathered (January 1, 2020). A full statistical analysis plan
will be developed before April 1, 2019.
Early daily mobilisation (experimental intervention group)
In addition to standard care (see below), the experimen-
tal intervention group is subjected to an early and daily
mobilisation protocol with HUT during their stay in the
intensive care unit and throughout the early stages of re-
habilitation. Mobilisation will be conducted using a tilt
table with an integrated stepping device, which activates
the venous pump and counteracts pooling of blood in
the lower extremities (ERIGO®, Hocoma, Volketswil,
Switzerland). The tilt-table intervention is applied once
daily, 5 days per week for 4 weeks during the stay in the
NICU. The duration of upright positioning is 20 min per
session. Within each session, the patient will be moved
to the tilt table and secured with straps and harness.
The patient is then mobilised stepwise to 30°, 50°, and
70° HUT at 1-minute intervals while blood pressure
(BP), heart rate (HR), respiratory rate, and peripheral
oxygen saturation are closely monitored. Cerebral perfu-
sion pressure (CPP) and intracranial pressure (ICP) are
monitored as clinically indicated. If at any time our pre-
determined safety limits for BP, CPP, ICP, or HR (Table 1)
are crossed, the patient is lowered to 0° tilt. When the
values have returned within the safety limits, the pro-
cedure is resumed until the patient has been in the
Fig. 2 Trial flow diagram. Abbreviations: GCS Glasgow Coma Scale, ICP intracranial pressure
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upright position for a maximum of 20 min or until a
total duration of 40 min for the HUT session has been
reached, whichever occurs first.
If the patient is discharged from the NICU to the de-
partment of neurorehabilitation/TBI unit before the
4-week intervention period has ended, training will con-
tinue at the latter institution with a prespecified tilt-table
protocol consisting of mobilisation twice a day on a simi-
lar tilt table. Patients who show functional improvement
beyond the scope of tilt-table training (for example, are
able to stand from a chair) before the trial period has
ended will have their experimental intervention with-
drawn and their final evaluation performed immediately
hereafter; subsequently, the standard rehabilitation regi-
men will be continued.
Some patients will be discharged from the NICU to a
temporary stay at another intensive care unit in the Cap-
ital Region of Copenhagen. In that case, the mobilisation
and assessments will be continued using a standard tilt
table (without the stepping device).
Standard care (experimental and control groups)
The experimental and control groups receive standard
rehabilitation as decided in collaboration between doc-
tors, nurses, and physiotherapists and will be moni-
tored during the trial. Only a small amount of time is
used on mobilising the patient to either the edge of the
bed or to a wheelchair whilst admitted to the NICU.
The physiotherapists’ main focus is on respiratory func-
tion and positioning to avoid bedsores. The patients in
the control group do not receive physical therapy on a
daily basis.
Trial duration
The trial intervention will consist of 4 weeks of mobili-
sation corresponding to 20 mobilisation sessions (Fig. 1).
The patients included will be followed until end of
in-hospital rehabilitation and again 1 year after injury.
Data collection
Information on patient characteristics (age, sex, diagno-
sis, comorbidities, functional status prior to this injury,
time since injury, and surgical procedures) is retrieved
from the patient charts. For patients receiving the ex-
perimental intervention, the number of training sessions
during the 4-week intervention period is recorded.
Outcomes are described below. There are two types of
outcomes: feasibility outcomes and exploratory clinical
outcomes.
Feasibility outcomes
The primary objective of this trial is to assess feasibility.
First, we will evaluate the number of patients we are able
to include in the trial during the 2-year inclusion period,
and a proportion of 60% or more of TBI patients who
are eligible for the trial is acceptable. Second, we will
evaluate the number of sessions applied in the experi-
mental intervention group. The intervention will be con-
sidered to be feasible if at least 60% of the intended
sessions (maximum of two per weekday in the trial for 4
weeks after randomisation, for a maximum of 20 ses-
sions in total) are given to at least 52% of the patients in
the intervention group. If a patient is transferred to an-
other department and it is not possible to apply the
intervention, we will count sessions as missing. If a pa-
tient dies, the number of applied and missing sessions is
recorded at the time of death. Both feasibility outcomes
are based on clinical judgement from the staff at the de-
partment and the trial investigators.
AEs, serious AEs (SAEs), ARs, serious ARs (SARs),
and suspected unexpected SARs will be monitored dur-
ing the trial counting the number of occurrences. Caus-
ality of AR will be assessed daily.
For a larger trial to be deemed feasible, both feasibility
outcomes need to be attained, meaning that more than
60% of eligible patients will participate and at least 52%
of the intervention group will receive more than 60% of
the intended interventions.
Exploratory clinical outcomes
The exploratory clinical outcomes are the CRS-R [20],
the Early Functional Ability (EFA) [21], and the Func-
tional Independence Measure (FIM) [22]. The CRS-R
[20] evaluates changes in consciousness. It is hierarchic-
ally ordered and composed of six categories evaluating
auditory, visual, motor, oromotor–verbal function, com-
munication, and arousal. The scale ranges from 0 to 23
points, and a higher score indicates a higher level of
function [20]. The evaluation will be carried out by two
assessors who are experienced at using the scale. These
assessors will be blinded to the patient’s treatment allo-
cation. To obtain a complete evaluation of the patient’s
progress, the EFA scale is included. The EFA scale is
constructed to fill the evaluation gap between the GCS
and FIM. The scale comprises 20 items, including mea-
sures of wakefulness, activities of daily living and cognitive
Table 1 Predetermined safety limits during head-up tilt
Absolute Systolic/Diastolic BP >80/50 mm Hg
CPP >50 mm Hg
HR <180 bpm
ICP <25 mm Hg
Relative Permitted decrease from baseline
systolic/diastolic BP
<30/15 mm Hg
Permitted increase in HR from baseline <30 bpm
Abbreviations: BP blood pressure, CPP cerebral perfusion pressure, HR heart
rate, ICP intracranial pressure
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abilities [21]; again, a higher score (range from 20 to
100 points) indicates a higher level of function. The
FIM consists of 18 items highlighting motor function,
ability to do activities of daily living and higher cogni-
tive functions ranging from 18 to 126 points, and a
higher score indicates a higher level of function. Scor-
ing will be conducted by the staff at the two depart-
ments. It is not possible to blind these assessors to the
randomisation procedure. The FIM has been thor-
oughly investigated in patients with TBI and has been
shown to be valid and reliable and have established
measures for detecting the minimal clinically important
difference [23, 24]. The FIM was chosen as an outcome
to track patient improvements over a long period of
time. Owing to the initial low levels of consciousness in
patients with severe TBI, combining the EFA and FIM
has been recommended for a more complete assess-
ment [25]. Preferably, the patient will be tested by
CRS-R at the same time of day. The FIM and the EFA
will be scored at the NICU by one tester with experi-
ence from the department of neurorehabilitation, who
will gather necessary information from the multidiscip-
linary team treating the patient. Assessment of the pa-
tients at the department of neurorehabilitation will be
performed by members of the clinical staff, who are ex-
perienced at using the two scales. The FIM, EFA, and
CRS-R will be applied at baseline, at 4 weeks and 3
months after the baseline assessment, and at 1 year
after the initial injury (Fig. 1).
Furthermore, length of stay at the two departments,
time until tilt-table training is no longer relevant, and
the duration of post-traumatic amnesia, as defined by
time from injury and until the patient regains coher-
ent day-to-day memory [26] are also registered. Dur-
ing the trial, the total amount of physical therapy
sessions allocated to the patients is measured in both
groups.
To address the haemodynamic changes during the
transition from the supine position to HUT, we will
measure non-invasive blood pressure by beat-to-beat
photopletysmography and HR by ECG (ADInstruments,
Oxford, UK), cerebral blood flow velocity (transcranial
Doppler, Multi-Dop® T digital, Compumedics Germany/
DWL, Singen, Germany), and partial pressure of carbon
dioxide in arterial blood (PaCO2) (ABL800, Radiometer,
Copenhagen, Denmark). The HUT test will take place
at baseline, after 2 weeks and after 4 weeks, or at the
end of the intervention period. The data are used to in-
vestigate orthostatic tolerance and cerebral autoregula-
tion as well as the patient’s baroreceptor sensitivity
(beat-to-beat variation). Furthermore, ECG will be re-
corded continuously for 5 days, immediately after the
patient has been included in the trial (ePatch, BioTe-
lemetry Technology Aps, Hørsholm, Denmark).
Statistical analyses
The primary feasibility outcome is the ratio between pa-
tients included and eligible patients. Eligible patients are
those who fulfil the inclusion criteria of our trial. For ex-
ample, if the number of randomly assigned participants
is 44 out of 60 eligible patients, then the proportion will
be 0.73 with a 95% confidence interval (CI) between 0.60
and 0.84. A proportion of 0.60 (the lower CI of the pro-
portion) or more randomly assigned patients will be ac-
ceptable for a future larger-scale trial. We strive for
having as large a proportion of eligible patients as partic-
ipants to make the latter as representative of the former
as possible and have arbitrarily set the acceptable lower
95% CI to be 60% or above. We will include a maximum
of 60 participants or as many as possible during the
24-month recruitment period.
The second feasibility outcome is defined as the num-
ber of HUT sessions applied during the 4-week interven-
tion period. In our clinical judgement, we believe that it
is satisfactory to be able to apply more than 60% of the
daily HUT sessions on weekdays for more than 70% or
at least 52% (the lower CI of the proportion) of the pa-
tients. Since a maximum of 30 patients will be randomly
assigned to the intervention, a binominal distribution is
calculated from the proportion of 70%, which gives a
lower 95% CI of 52%.
The number of patients with at least one AE or SAE
during the intervention period will be analysed as ex-
ploratory feasibility outcomes using logistic regression
adjusted for the protocol-specified stratification variable.
Moreover, we will compare the proportions and severity
in the two intervention groups.
Baseline data will be used to describe the population.
Data will be analysed by using SAS Enterprise version
7.11 (SAS Institute Inc., Cary, NC, USA). A binominal
distribution will be used to calculate the 95% CI for our
primary feasibility outcome as the proportion of ran-
domly assigned patients from the eligible patients.
The clinical exploratory outcomes will not undergo
traditional statistical testing, as this is a small feasibility
trial with large risks of random errors. However, in order
to test the feasibility of the analyses and for exploratory
purposes, outcomes will be analysed and P values will be
presented. P values of any size will not be interpreted as
“significant”.
The CRS-R, FIM, and EFA as well as the physiological
measures of mean arterial pressure, HR, cerebral blood
flow, and the dynamic autoregulation index contain mul-
tiple measurement points and will be analysed accord-
ingly with analysis of variance or other linear regression
models for repeated measures. Missing data will be
treated with the multiple imputation method.
Dynamic cerebral blood flow autoregulation is ana-
lysed as the ratio between mean arterial pressure and
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cerebral blood flow velocity. For this, a Pearson correl-
ation coefficient of 30 mean values of mean arterial pres-
sure and cerebral blood flow each consisting of 10 s of
measurements are correlated in the supine position and
during maximum HUT [12, 27]. This gives two values of
the so-called Mx index per tilt test. Baroreceptor regula-
tion is assessed by using data from the ECG waves to
conduct a power spectral analysis of the RR intervals.
The purpose is to analyse the low-frequency content
(0.05 to 0.15 Hz), which is assumed to reflect the baro-
receptor activity, as well as the high-frequency content
(0.15 to 0.35 Hz), which is related mainly to parasympa-
thetic activity [28].
All analyses will be intention-to-treat using multiple
imputations to account for missing data as described by
Jakobsen et al. [29]. Analyses will be conducted blinded
with the two intervention groups coded as, for example,
0 and 1. After the drawing of conclusions, the blinding
will be broken.
Discussion
Early physical rehabilitation has previously been associ-
ated with improved outcome in patients with TBI in a
cohort study [13]. The pilot study published by Frazzitta
et al. showed promising results when starting physical
rehabilitation early in 31 patients with ABI, of whom 12
were affected by TBI [30]. Nevertheless, there is a lack
of studies investigating the causal relationship between
early physical rehabilitation and long-term outcome.
Andelic et al. conducted a quasi-randomised cohort
study on the effects of early rehabilitation at the inten-
sive care unit in patients with TBI [13]. Although the
consistency of the rehabilitation paradigm was unspeci-
fied, they did observe a benefit of this intervention as
measured by the Glasgow Outcome Scale Extended and
the Disability Rating Scale after 12 months [13]. This
trial intends to lay the foundation for a larger-scale mul-
ticentre randomised clinical trial, investigating whether
the patients are able to tolerate HUT, whether the inter-
vention is practically feasible, and whether the outcomes
are improved. A trial comparing short- and long-term
functional outcomes after standard care compared with
early mobilisation should also assess the effects of mo-
bilisation on haemodynamic regulation which has previ-
ously been associated with poor outcome or death [11,
12], in an attempt to identify potential predictors of
long-term recovery. The trial is designed aiming for a
low risk of bias using centralised randomisation, blinded
outcome assessors where possible, and blinded statistical
analyses [31–33]. However, it is not possible to blind the
patients or care givers, which may lead to risk of bias.
Furthermore, given the small sample size and the het-
erogeneous trial population, any differences we find be-
tween groups may be due to selection bias or random
errors or both [33–35]. Therefore, any result should be
interpreted with great caution.
Investigating AEs and ARs is with limitations. Whether
or not there is a direct causal relation between an inci-
dence and an AE and the intervention can in many ways
be subjective and hard to determine. Nevertheless, we feel
confident that the experienced staff can provide support
in informing when in doubt. We believe it is important to
do this feasibility trial as a randomised clinical trial since it
is likely to affect the decision of entering the trial.
Whether the mobilisation intervention is feasible could
have been answered in a classic observational study.
It is difficult to provide sufficient evidence for the gen-
eral assumptions presented in this protocol that longer
periods of bed rest may influence the baroreceptor sen-
sitivity and that early mobilisation may re-establish it.
Using HR variability to assess regulation of the auto-
nomic nerve system has been the subject of debate but
is a relatively simple, non-invasive tool, even though
more sophisticated and invasive measures could be used
for measuring sympathetic nerve activity, such as direct
recording of single-fibre muscle sympathetic nerve
activity.
If a larger multicentre randomised clinical trial is
deemed feasible, the data gathered in the present trial
should be of great use. The required sample size of a lar-
ger randomised clinical trial shall be calculated on the
basis of the data from the likely effects from the present
trial as well as evidence from updated systematic reviews
of randomised clinical trials. Moreover, the financial esti-
mates of conducting a larger trial will be clearer from es-
timates of time consumption based on the present
feasibility trial.
Trial status
Enrolment commenced on January 2, 2017. At present, 34
patients have been randomly assigned. We will continue in-
cluding patients until January 1, 2019 or until 60 patients
are included, whichever occurs first, and will complete the
last 1-year follow-up assessment in December 2019.
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